Trulicity is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)]. Prior serious hypersensitivity reaction to dulaglutide or to any of the product components.
Indications and Usage for Trulicity Trulicity® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The recommended initiating dose of Trulicity is 0.75 mg once weekly. The dose may be increased to 1.5 mg once weekly for additional glycemic control.
Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of patients on Trulicity in clinical studies.
Trulicity has been studied as monotherapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione, sodium-glucose co-transporter-2 inhibitors (SGLT2i) with or without metformin, basal insulin with or without metformin, and prandial insulin with or without metformin.
Coding Table InformationCodeDescriptor Generic NameDescriptor Brand NameJ3490UNCLASSIFIED DRUGSAlbiglutide, Tanzeum®J3490UNCLASSIFIED DRUGSDulaglutide, Trulicity®J3490UNCLASSIFIED DRUGSMethotrexate - Solution Auto-injector Non Chemotherapeutic, Otrexup™, Rasuvo®J3490UNCLASSIFIED DRUGS34 more rows
ICD-10 Code Z79. 4, Long-term (current) use of insulin should be assigned to indicate that the patient uses insulin for Type 2 diabetes mellitus (Category E11* codes). Z79. 4 should NOT be used for Type 1 diabetes mellitus (Category E10* codes).
Type 2 diabetes mellitus without complications The 2022 edition of ICD-10-CM E11. 9 became effective on October 1, 2021. This is the American ICD-10-CM version of E11.
Coding Diabetes Mellitus in ICD-10-CM: Improved Coding for Diabetes Mellitus Complements Present Medical ScienceE08, Diabetes mellitus due to underlying condition.E09, Drug or chemical induced diabetes mellitus.E10, Type 1 diabetes mellitus.E11, Type 2 diabetes mellitus.E13, Other specified diabetes mellitus.
Trulicity is a non-insulin option that helps your body release the insulin it's already making. In studies, Trulicity has been proven to lower blood sugar levels. People taking Trulicity may notice better blood sugar numbers before eating in the morning (fasting blood sugar).
Type 2 diabetes mellitus E11-code to identify control using:insulin ( ICD-10-CM Diagnosis Code Z79.4. Long term (current) use of insulin. ... oral antidiabetic drugs ( ICD-10-CM Diagnosis Code Z79.84. Long term (current) use of oral hypoglycemic drugs. ... oral hypoglycemic drugs ( ICD-10-CM Diagnosis Code Z79.84.
ICD-Code E11* is a non-billable ICD-10 code used for healthcare diagnosis reimbursement of Type 2 Diabetes Mellitus. Its corresponding ICD-9 code is 250. Code I10 is the diagnosis code used for Type 2 Diabetes Mellitus.
ICD-10 code Z13. 1 for Encounter for screening for diabetes mellitus is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10 code: E11. 9 Type 2 diabetes mellitus Without complications.
Table 5ICD-9-CM diagnosis codes defining diabetesDescriptionICD-9-CM codeDiabetes mellitus without mention of complications250.0xDiabetes with ketoacidosis250.1xDiabetes with hyperosmolarity250.2xDiabetes with other coma250.3x8 more rows
5A11 Type 2 diabetes mellitus - ICD-11 MMS.
E11. 22 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
ICD-10 code E10. 9 for Type 1 diabetes mellitus without complications is a medical classification as listed by WHO under the range - Endocrine, nutritional and metabolic diseases .
2022 ICD-10-CM Diagnosis Code E10. 9: Type 1 diabetes mellitus without complications.
Table 1: HCPCS/CPT Codes and DescriptorsHCPCS/CPT CodesCode Descriptors82947Glucose; quantitative, blood (except reagent strip)82950Glucose; post glucose dose (includes glucose)82951Glucose Tolerance Test (GTT); three specimens (includes glucose)83036Hemoglobin A1C
Type 2 diabetes is a chronic disease. It is characterized by high levels of sugar in the blood. Type 2 diabetes is also called type 2 diabetes mellitus and adult-onset diabetes. That's because it used to start almost always in middle- and late-adulthood.
The ICD-10-CM Alphabetical Index links the below-listed medical terms to the ICD code Z79.899. Click on any term below to browse the alphabetical index.
This is the official approximate match mapping between ICD9 and ICD10, as provided by the General Equivalency mapping crosswalk. This means that while there is no exact mapping between this ICD10 code Z79.899 and a single ICD9 code, V58.69 is an approximate match for comparison and conversion purposes.
Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is a fusion protein that consists of 2 identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence covalently linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain by a small peptide linker and is produced using mammalian cell (Chinese hamster ovary) culture. The GLP-1 analog portion of dulaglutide is 90% homologous to native human GLP-1 (7-37). Structural modifications were introduced in the GLP-1 part of the molecule responsible for interaction with the enzyme dipeptidyl-peptidase-IV (DPP-4). Additional modifications were made in an area with a potential T-cell epitope and in the areas of the IgG4 Fc part of the molecule responsible for binding the high-affinity Fc receptors and half-antibody formation. The overall molecular weight of dulaglutide is approximately 63 kilodaltons.
The REWIND trial (NCT01394952) was a multi-national, multi-center, randomized, placebo-controlled, double-blind trial. In this study, 9901 adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors were randomized to Trulicity 1.5 mg or placebo both added to standard of care. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component Major Adverse Cardiovascular Events (MACE) outcome, which included CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.
Trulicity lowers fasting glucose and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus. The reduction in fasting and postprandial glucose can be observed after a single dose.
There are no data on the presence of dulaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. The presence of dulaglutide in milk of treated lactating animals was not determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Trulicity and any potential adverse effects on the breastfed infant from Trulicity or from the underlying maternal condition.
Trulicity delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of Trulicity [see Dosage and Administration ( 2.1 )]. The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, Trulicity 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree [see Clinical Pharmacology ( 12.3 )]. There is limited experience with the use of concomitant medications in clinical trials with Trulicity doses of 3 mg and 4.5 mg.
Use of Trulicity may be associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions ( 6.1 )]. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
Patients receiving Trulicity in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions ( 6.1) and Drug Interactions ( 7 )].